Why is GENB down?
Down 33% from Nov 9 to Nov 20 while the S&P 500 fell 8%.
- Its Nov 12 results:
−2Volatility
Down 33% from Nov 9 to Nov 20 while the S&P 500 fell 8%.
−2Volatility
GENB's Quality Score fell 1 point on Fri, Nov 20, to -1. It did not trade higher than the day before.
New listing, trading since Feb 27, 2026. 186 trading days so far, so 1 of the 14 chart checks waits for more history.
Follow GENB's trial news. Pro members can get an alert when Generate Biomedicines files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Holding it back | Moves 11.4% a day with no profit behind it |
| Latest filing | 8-K, Nov 12 |
Sat Feb 27: One year since its IPOListed Feb 27, 2026 at $16.
After its last 3 reports it closed -7.4% on average, higher 0 of 3 times.
$404M in cash
No shelf registration or at-the-market program on file in the last three years.
Director Frances Arnold sold 11,409 shares on Oct 29, under a planned sale. 6 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
GENB is #113 of 273 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 113 |
Expected to report Thu Mar 25, before the open (in 124 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
A loss of $0.68 a share.
“This revenue reflects developments in the ongoing Amgen and Novartis research programs and that Generate is near completion of its performance obligations under both agreements.”
GENB's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“The increase was driven primarily by continued investment in the GB-0895 Phase 3 SOLAIRIA clinical trials in severe asthma and was partially offset by a decrease in external discovery and other program related costs.”
From its results filing (SEC filing · Nov 12)
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 12, 2026 | -6.6% | -6.8% | -23.1% |
| Aug 6, 2026 | -2.7% | -4.1% | +4.1% |
| May 7, 2026 | -3.4% | -11.2% | +6.0% |
RSI 33.3, MACD below signal. Not scored.
Officers and directors with a Form 4 in the last 12 months.
In ETFs: GENB is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
Listed on Nasdaq on Feb 27, 2026, and is 40% below its $16 offer price now. Its IPO filing and first days
GENB scores -1 today, which Breakaway calls Poor. It is #113 of 273 in Biotech by Quality Score, with 1 of 14 chart checks firing. Down 33% from Nov 9 to Nov 20 while the S&P 500 fell 8%. Shares: 3.9 times the count a year ago (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
GENB scores -1 today, which Breakaway calls Poor (below zero). That is #113 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind GENB's -1.
Expected to report Thu Mar 25, before the open, a date Breakaway expects from the company's usual timing; the company has not confirmed it. GENB closed higher after 0 of its last 3 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.